Investor Presentation

Here's a summary of the attached investor presentation: **Financial Highlights:** Q1 FY26 revenue hit ₹320 Cr (+31.9% YoY), EBITDA ₹34 Cr (+24.5% YoY, 10.8% margin), and PAT ₹21 Cr (+52.8% YoY, 6.5% margin). Gross margins were 33.1%. FY25 showed healthy 16% ROCE and 11% ROE. **Strategic Initiatives & Growth Drivers:** Four new products target commercialization in 2-3 quarters.

R&D facilities are expanding with investments adding new chemistries.

New manufacturing block and capacity debottlenecking are underway, due in six quarters. **Business Developments:** Three MOUs were signed for export-oriented products.

A new agrochemical herbicide was commercialized domestically in Q1. **Market Position & Competitive Advantage:** PCCPL operates in Agrochemicals, Pharma, Industrial Chemicals, with strong manufacturing (2000 KL reactor, ZLD) and R&D (doubling FY26). It's positioned as a preferred CRAMS provider, benefiting from global supply chain shifts. **Investor Implications:** Strong Q1 FY26 results, promising product pipeline, and significant R&D/capacity investments signal positive growth potential.

Strategic partnerships and high-value segment focus reinforce a favorable long-term outlook.